Comparative Pharmacology
Head-to-head clinical analysis: CYCLOCORT versus DESONATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYCLOCORT versus DESONATE.
CYCLOCORT vs DESONATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive actions. Suppresses cytokine production, inhibits phospholipase A2, and reduces prostaglandin synthesis.
Desonide is a corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties. It acts by inducing phospholipase A2 inhibitory proteins, thereby reducing arachidonic acid release and subsequent prostaglandin and leukotriene synthesis.
Apply a thin film topically to affected area twice daily (morning and evening). Not for ophthalmic use.
Apply 0.05% cream, lotion, or ointment topically to affected skin twice daily.
None Documented
None Documented
3.5 hours (terminal); clinical effect duration longer due to tissue binding.
Terminal half-life is approximately 3-4 hours for desonide; clinically, this supports twice-daily dosing.
Primarily hepatic metabolism; inactive metabolites excreted renally (<1% unchanged) and in feces (biliary).
Renal (approximately 75% as metabolites, <5% unchanged) and fecal (approximately 25%).
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid